1-2 of 2
Frederik Lersch, RN
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 ( IDH2 ) Mutations: Interim Phase II Results from an Ongoing, Randomized Study

Courtney D. DiNardo, MD MSc, Andre C. Schuh, MD, Eytan M. Stein, MD, Pau Montesinos Fernandez, MD PhD, Andrew Wei, MBBS, FRACP, FRCPA, PhD, Stephane De Botton, Amer M. Zeidan, MBBS, MHS, Amir T. Fathi, MD, Lynn Quek, MD PhD, Hagop M. Kantarjian, MD, Mark G. Frattini, MD, Frederik Lersch, RN, Jing Gong, PhD, Aleksandra Franovic, PhD, Kyle MacBeth, PhD, Paresh Vyas, MD PhD, Hartmut Döhner, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 643.
https://doi.org/10.1182/blood-2019-130362
Published: 2019
Journal Articles

Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation Is Safe, Effective, and Leads to MRD-Negative Complete Remissions

Eytan M. Stein, MD, Courtney D. DiNardo, MDMSc, Amir T. Fathi, MD, Alice S. Mims, MD, Keith W. Pratz, MD, Michael R. Savona, MD, Anthony S. Stein, MD, Richard M. Stone, MD, Eric S. Winer, MD, Christopher S. Seet, MD, Hartmut Döhner, MD, Daniel A Pollyea, MD, James K McCloskey, MD, Olatoyosi Odenike, MD, Bob Lowenberg, MD, Gert J. Ossenkoppele, MD PhD, Prapti A. Patel, MD, Mikhail Roshal, MD PhD, Frederik Lersch, RN, Salah Nabhan, MS, Sung Choe, PhD, Hongfang Wang, PhD, Lei Hua, PhD, Caroline Almon, MS, Michael Cooper, MD, Martin S. Tallman, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 560.
https://doi.org/10.1182/blood-2018-99-110449
Published: 2018